CANCELLED: 6th ESO-ESMO Latin-American Masterclass in Clinical Oncology
Not eligible for ESCO credits
22.04.2020 - 26.04.2020
Buenos Aires, Argentina
MASTERCLASS
Important information
On behalf of ESO and ESMO, we would like to inform you that due to the ongoing Coronavirus (COVID-19) crisis we have made the difficult decision to cancel the 6th ESO-ESMO Latin-American Masterclass in Clinical Oncology, 22-26 April 2020, Buenos Aires, Argentina.
We deeply regret having to take this decision but we feel that in the current climate we all need to do our part in trying to limit the diffusion of the virus as much as possible and this was the only decision possible considering your role in society as medical staff.
We have discussed the possibility of postponing the event to later this year, but due to other already planned activities we have decided that postponing is not a viable solution.
We apologize for any inconvenience caused but we think you’ll all agree that this solution was unavoidable.
Description
Chairs: A. Cervantes, ES - N. Pavlidis, GR - R.A. Stahel, CH
Scientific Co-ordinators: M. Aapro, CH - F. Cardoso, PT
FOREWORD
The Masterclass is the most structured ESO educational activity whose format has been established and presented in Europe for over a decade. The success of the teaching method has been confirmed by the events held also in other parts of the world as well as by the five editions held in Latin America. It is with pleasure and gratefulness for the consideration of the local community, that ESO announces the sixth edition to be held in the region in 2020.The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized by ESMO and other evidence-based guidelines will be cited.
Participants will deliver case presentations within tumour boards and small groups and discuss them with the experts.
As for all Masterclasses, the number of participants will be limited and admission will be by competitive application only.
Admitted participants will be granted free registration and half-board accommodation for the duration of the Masterclass.
TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. The clinical sessions will be complemented by tumour board discussions supported by regional tutors.
Furthermore, participants will deliver case presentations within small groups and discuss these with the experts.
In preparation of the attendance, participants will be requested to follow four selected e-ESO sessions (www.e-eso.net).
All participants will reside at the course venue and participation is compulsory throughout the course.
The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.
LEARNING OBJECTIVES
• Improve medical oncologists’ skills
• Practicing case discussion
• Deep focus on breast, gastro-intestinal, genitourinary, gynaecological, head and
neck and lung cancers
• Compact update on further topics of interest
MAIN TOPICS
• Breast cancer
• Gastro-intestinal cancers
• Genito-urinary cancers
• Gynaecological cancers
• Head and neck cancer
• Lung cancer
The Latin-American Masterclass in Clinical Oncology is an ESO-ESMO joint event |
![]() |
|||||
In collaboration with | ![]() |
|||||
Under the auspices of |
In this review, the authors summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. The MCO has become a major educational event of ESO, intending to educate young oncologists from various countries within or outside Europe, providing an up-to-date interactive program based on solid evidence for all presented topics.
"Reprinted from Critical Reviews in Oncology / Hematology, Pavlidis et al, Copyright (2019)
https://doi.org/10.1016/j.critrevonc.2019.07.022 with permission from Elsevier”
• Download PDF document
Faculty
FACULTY
M.S. Aapro, Clinique de Genolier, Genolier, CH
S. Bella, Universidad Católica de Córdoba and the Clínica Universitaria Reina Fabiola, Córdoba, AR
F. Cardoso, Champalimaud Cancer Center, Lisbon, PT
F. Cavalli, Oncology Institute of Southern Switzerland, Bellinzona, CH
A. Cervantes, University Clinical Hospital, Valencia, ES
M. Chacon, Instituto Alexander Fleming, Buenos Aires, AR
G. Curigliano, European Institute of Oncology, Milan, IT
F. Esteso, Instituto Alexander Fleming, Buenos Aires, AR
S.X. Franco, Clinical del Country, Bogota, CO
F. Geara, American University of Beirut Medical Center, Beirut, LB
G.H. Giornelli, Instituto Alexander Fleming, Buenos Aires, AR
S. Iseas, Hospital Udaondo, Buenos Aires, AR
D. Lorusso, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
C. Martin, Instituto Alexander Fleming, Buenos Aires, AR
N. Mottet, University Jean Monnet, Saint Etienne, FR
J. Nadal, Instituto Alexander Fleming, Buenos Aires, AR
N. Pavlidis, University Hospital, Ioannina, GR
F.A. Peccatori, European School of Oncology and European Institute of Oncology, Milan, IT
F. Penault-Llorca, Centre Jean Perrin, Clermont-Ferrand, FR
C. Rolfo, University of Maryland School of Medicine, Baltimore, US
J.P. Sadé, Instituto Alexander Fleming, Buenos Aires, AR
C. Sessa, Oncology Institute of Southern Switzerland, Bellinzona, CH
R.A. Stahel, University Hospital, Zurich, CH
E. Van Cutsem, University Hospital Gasthuisberg, Leuven, BE
J.J. Zarbá, Hospital Zenon Santillan, San Miguel de Tucuman, AR
General information
ORGANISING SECRETARIAT
European School of Oncology
Piazza Indipendeza 2, 6500 Bellinzona, Switzerland
Luis Carvalho, Ph: +41 91 820 09 58, E-mail: lcarvalho@eso.net
Laura Richetti, Ph +41 91 820 09 51, E-mail: lrichetti@eso.net
LANGUAGE
The Masterclass will be held in English and translation will not be provided.
INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the event. Participants will be advised to take out their own personal and travel insurance coverage.
CME AND ESMO MORA ACCREDITATION AND CERTIFICATES
The 6th ESO-ESMO Latin-American Masterclass in Clinical Oncology, Buenos Aires, Argentina, 22/04/2020-26/04/2020 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The programme has been granted up to 32 European CME credits (ECMEC) . Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
Participants will be entitled to receive a certificate of attendance at the close of the event by completing the on-line evaluation questionnaire.
Furthermore, application for the ESMO-MORA points is in process.
Application
PARTICIPANT’S PROFILE
• Age between 30 and 40 years
• At least 3 years’ experience in medical oncology (or clinical oncology)
• Involvement in scientific activities (desirable)
• Intermediate level of English language
• Practicing in Latin America
The application outcome will be notified by e-mail by begin of February.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and half-board accommodation.
THE APPLICATION DEADLINE HAS PASSED (19 JANUARY 2020)
Programme
22 April
12:15 | Welcome and introduction Chairs |
|
12:30 | Clinical session Gynaecological Cancers Chairs: C. Sessa, CH - D. Lorusso, IT |
|
Pathologist's impact in gynaecological tumour F. Penault-Llorca, FR |
||
Discussion | ||
Ovarian Cancer: Surgical and systemic treatment D. Lorusso, IT |
||
Discussion | ||
Endometrial Cancer: Local and systemic treatment C. Sessa, CH |
||
Discussion | ||
Cervical Cancer: Local and systemic treatment D. Lorusso, IT |
||
Discussion | ||
14:30 | Coffee break | |
14:50 | Spotlight session Primary and secondary prevention of cervical cancer J.J. Zarbá, AR |
|
15:10 | Discussion | |
15:20 | Selected participants present their national situation ("How is cancer treated in my country") | |
15:30 | Discussion | |
15:40 | Tumour board Gynaecological Cancer C. Sessa,CH - D. Lorusso, IT Local Tutors: G. Giornelli, AR Participants' case presentations |
|
16:40 | Group sessions Clinical case presentations by participants Chairs 1: C. Sessa, CH - Co-chair: F. Geara, LB Chair 2: D. Lorusso, IT - Co-chair: S. Bella, AR |
|
17:40 | The role of surgery in ovarian cancer - Video session | |
18:20 | Discussion | |
20:00 | Welcome dinner |
23 April
8:30 | Clinical session Breast cancer (I) Chair: F. Cardoso, PT - Co-Chair: F. Geara, LB |
|
What the clinician needs to know about breast pathology and sample quality F. Penault-Llorca, FR |
||
Genomic tests in clinical practice F. Cardoso, PT |
||
Discussion | ||
(Neo-) adjuvant chemotherapy and biological agents G. Curigliano, IT |
||
Discussion | ||
Neoadjuvant/adjuvant endocrine therapy F. Cardoso, PT |
||
Radiation therapy in early breast cancer F. Geara, LB |
||
Discussion | ||
11:10 | Coffee break | |
11:30 | Clinical session Breast cancer (II) Chair: G. Curigliano - Co-Chair: F. Geara, LB |
|
Recommended management of HER-2+ advanced breast cancer F. Cardoso, PT |
||
Discussion | ||
Recommended management for triple-negative advanced breast cancer G. Curigliano, IT |
||
Discussion | ||
Recommended management for ER+ advanced breast cancer S.X. Franco, CO |
||
Discussion | ||
13:05 | Lunch | |
14:00 | Tumour board Breast cancer F. Cardoso, PT - G. Curigliano, IT - S.X. Franco, CO - J. Nadal, AR Participant's case presentations |
|
16:00 | Coffee break | |
16:15 | Group sessions Chair 1: F. Cardoso, PT - Co-Chair: J. Nadal, AR Chair 2: G. Curigliano, IT - S.X. Franco, CO Clinical case presentations by participants |
|
18:00 | Spotlight session The reality of clinical trials in Latin America C. Rolfo, US |
|
18:20 | Discussion | |
18:30 | Spotlight session Fertility preservation and pregnancy in cancer patients F. Peccatori, IT |
|
18:50 | Discussion |
24 April
8:30 | Clinical session Lung cancer Chair: R. Stahel, CH - Co-Chair: F. Geara, LB |
|
Advanced NSCLC with oncogenic driver mutation C. Rolfo, US |
||
Discussion | ||
Advanced Discussion NSCLC without oncogenic driver mutation R. Stahel, CH |
||
Mutimodality treatment of stage III and oligometastatic NSCLC C. Rolfo, US |
||
Discussion | ||
Multimodality therapy of small cell lung cancer R. Stahel, CH |
||
Discussion | ||
10:30 | Coffee break | |
10:50 | Selected participants present their national situation ("How is cancer treated in my country") | |
11:00 | Discussion | |
11:10 | Tumour board Lung cancer R. Stahel, CH - C. Rolfo, US - F. Geara, LB - C. Martin, AR |
|
Participant's case presentations | ||
13:00 | Lunch | |
14:35 | Spotlight session Title to be confirmed F. Cavalli, CH |
|
14:25 | Discussion | |
14:35 | Group sessions Chair: R. Stahel, CH - Co-Chair: C. Martin, AE Chair 2: C. Rolfo, US - F. Geara, LB Clinical case presentations by participants |
|
16:35 | Coffee break | |
16:55 | Spotlight session How to fight financial toxicity R. Stahel, CH |
|
17:20 | Discussion | |
17:30 | Spotlight session Cancer of unknown primary N. Pavlidis, GR |
|
17:50 | Discussion |
25 April
8:30 | Clinical session Gastro-intestinal tumours Chair: E. Van Cutsem, BE - Co-chair: A. Cervantes, ES |
|
What you have to obtain from the pathologists to make a good treatment decision F. Penault-Llorca, FR |
||
Discussion | ||
Adjuvant and neo-adjuvant treatment of colorectal cancer E. Van Cutsem, BE |
||
Discussion | ||
Systemic treatment in advanced CRC E. Van Cutsem, BE |
||
Discussion | ||
Management of early rectal Cancer A. Cervantes, ES |
||
Discussion | ||
10:30 | Coffee break | |
10:50 | Treatment of early esophageal and gastric cancer A. Cervantes, ES |
|
Discussion | ||
Systemic treatment of advanced gastric cancers E. Van Cutsem, BE |
||
Discussion | ||
Systemic treatment of pancreatic and biliary tract cancer E. Van Cutsem, BE |
||
Discussion |
||
12:20 | Selected participants present their national situation ("How is cancer treated in my country") | |
12:30 | Discussion | |
12:40 | Tumour board Gastro-intestinal tumours A. Cervantes - E. Van Cutsem – Tutor: S. Iseas, AR Participant's case presentations |
|
13:40 | Lunch | |
14:30 | -15:00 Spotlight session Principles of geriatric oncology M. Aapro, CH |
|
14:50 | Discussion | |
15:00 | Group sessions Chair 1: A. Cervantes, ES - Co-chair: S. Iseas, AR Chair 2: E. Van Cutsem, BE - Co-chair: F. Esteso, AR Part Clinical case presentations by participants |
|
17:00 | Coffee break | |
17:20 | Spotlight session Cancer supportive care | |
17:45 | Discussion | |
17:50 | Spotlight session How to operate colon cancer (video) | |
18:15 | Discussion | |
20:15 | Farewell Dinner |
26 April
8:00 | Clinical session Genito-urinary Cancers Chair: N. Mottet, FR, BE - Co-chair: J.P. Sadé |
|
Management of localized prostate cancer F. Geara, LB |
||
Discussion | ||
Treatment of metastatic castration sensitive prostate cancer J.P. Sadè, AR |
||
Discussion | ||
Castration-resistant prostate cancer N. Mottet, FR |
||
Discussion | ||
Treatment of bladder cancer J.P. Sadè, AR |
||
Discussion | ||
Metastatic renal cancer: Evidence-based treatment N. Mottet, FR |
||
Discussion | ||
10:30 | Coffee break | |
10:50 | Tumour board Genito-urinary cancers N. Mottet, FR - J.P. Sadè, AR - Tutor: M. Chacon, AR Participant's case presentations |
|
11:50 | Group sessions Chair 1: N. Mottet, FR - Co-Chair: M. Chacon, AR Chair 2: J.P. Sadè, AR - Co-Chair: M. Orlando, AR Part Clinical case presentations by participants |
|
13:00 | Learning assessment test | |
14:00 | Closing Remarks and Awards | |
14:15 | Lunch followed by departures |